Journal of Cancer Research and Therapeutics Close
 

Figure 1: Immune-related pneumonitis following treatment with a PD-1 inhibitor. (a) After 7 months of pembrolizumab, a chest CT image showed a small ground-glass opacity in the right lung. (b) After 9 cycles of pembrolizumab, a CT scan of the chest indicated an obvious new lesion accompanied by a solitary thick-walled cavity in the right lung. Metastatic pulmonary node was suspected, but immune-related pneumonitis and secondary infections needed to be distinguished. (c) After immunotherapy-related pneumonitis was identified, this patient was treated continuously with oral prednisolone. His symptoms improved over 2 weeks. CT: Computed tomography

Figure 1: Immune-related pneumonitis following treatment with a PD-1 inhibitor. (a) After 7 months of pembrolizumab, a chest CT image showed a small ground-glass opacity in the right lung. (b) After 9 cycles of pembrolizumab, a CT scan of the chest indicated an obvious new lesion accompanied by a solitary thick-walled cavity in the right lung. Metastatic pulmonary node was suspected, but immune-related pneumonitis and secondary infections needed to be distinguished. (c) After immunotherapy-related pneumonitis was identified, this patient was treated continuously with oral prednisolone. His symptoms improved over 2 weeks. CT: Computed tomography